PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced that it will disclose its Q1 2023 financial results and operational highlights on May 10, 2023, before U.S. market opening. This marks a critical period as the company aims to enhance surgical outcomes with its innovative technology. A conference call is scheduled for 8:30 AM ET that day to discuss the results and future business updates.

PolyPid's lead product candidate, D-PLEX100, is undergoing Phase 3 trials targeting surgical site infections, while the company is also exploring OncoPLEX for treating solid tumors, starting with glioblastoma. Investors and analysts are eagerly awaiting insights that could influence stock performance.

Positive

• PolyPid's D-PLEX100 is in Phase 3 trials, potentially leading to market approval.
• The upcoming financial results and operational updates may positively impact investor sentiment.

Negative

• None.

PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 10, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, May 10, 2023
Time:	8:30 AM Eastern Time
Conference Call:	https://register.vevent.com/register/BI4643e991c9604c539af94f4d0682274c
Webcast:	https://edge.media-server.com/mmc/p/2ymp9poq

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com

 

FAQ

What are PolyPid's Q1 2023 financial results release date and time?

PolyPid will report its Q1 2023 financial results on May 10, 2023, at 8:30 AM ET.

What is the ticker symbol for PolyPid?

The ticker symbol for PolyPid is PYPD.

What is the purpose of the conference call on May 10, 2023?

The conference call will discuss Q1 2023 financial results and provide updates on business operations.

What is D-PLEX100 and its current status?

D-PLEX100 is PolyPid's lead product candidate in Phase 3 clinical trials for the prevention of surgical site infections.

What other product is PolyPid developing?

PolyPid is also developing OncoPLEX for treating solid tumors, starting with glioblastoma.